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Introduction {#sec001}
============

Lymphoma continues to be the most common form of hematological malignancy worldwide \[[@pone.0210224.ref001],[@pone.0210224.ref002]\]. Lymphoma is a heterogeneous group of biologically and clinically distinct neoplasms and have been historically divided into two distinct categories: non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) \[[@pone.0210224.ref003]\]. Although major progress has been made in the treatment of patients with lymphoma, many still fail to achieve a response or subsequently relapse \[[@pone.0210224.ref004]\]. These patients are not easily identified by existing pretreatment prognostic indexes such as the IPI (international prognostic index), IPS (international prognostic score for Hodgkin lymphoma \[HL\]), FLIPI (prognostic score for follicular lymphoma), MIPI (prognostic score for mantle cell lymphoma), and PIT (prognostic index for peripheral T cell lymphoma) or by conventional computed tomography (CT)--based response assessment \[[@pone.0210224.ref005]--[@pone.0210224.ref009]\]. Therefore, there is an urgent need for new prognostic and predictive markers which permit an accurate and early identify high-risk patient categories.

^\[18\]^Fluorine fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) has been recognized by the 2014 International Conference on Malignant Lymphoma imaging consensus guidelines as the standard imaging modality to evaluate glucose metabolism in fluorodeoxyglucose (FDG)-avid lymphoma tumors \[[@pone.0210224.ref010],[@pone.0210224.ref011]\]. Its value for prognosis prediction at interim and end treatment has been recently investigated \[[@pone.0210224.ref012]--[@pone.0210224.ref014]\]. Many studies have also showed that quantitative volumetric parameters derived from baseline ^18^F-FDG PET such as total metabolic tumor volume (TMTV) or total lesion glycolysis (TLG) could predict outcome in diffuse large B-cell lymphoma \[[@pone.0210224.ref015]--[@pone.0210224.ref017]\], in follicular lymphoma \[[@pone.0210224.ref018]\], in peripheral T-cell lymphoma \[[@pone.0210224.ref019]\], in extranodal natural killer/T-cell lymphoma \[[@pone.0210224.ref020]\] and in Hodgkin lymphoma \[[@pone.0210224.ref021],[@pone.0210224.ref022]\]. However, those studies evaluating the prognostic values of pre-therapy TMTV and TLG in in patients with various lymphoma subtypes showed inconclusive and contradictory results \[[@pone.0210224.ref023]\].

Therefore, the purpose of this meta-analysis was to evaluate the prognostic value of baseline TMTV or TLG by PET/CTin patients with lymphoma, in order to provide more evidence of their clinical value as prognostic biomarkers.

Materials and methods {#sec002}
=====================

Inclusion and exclusion criteria {#sec003}
--------------------------------

A computerized search of PubMed, Embase and Cochrane was conducted to find relevant studies published prior to May 01, 2018. The following search terms were used: (\"lymphoma\"\[MeSH Terms\] OR lymphom\*\[All Fields\] OR lymphoproliferative \[All Fields\] OR hodgkin\*\[All Fields\] OR non-hodgkin\* \[All Fields\]) AND (\"Tomography, emission-computed\"\[MeSH Terms\] OR (\"positron emission tomograpy\"\[MeSH Terms\]) OR (computed \[All Fields\] AND tomograph\*\[All Fields\])) AND (prognos\* OR predict\* OR surviv\* OR overall survival\* OR recurrence\* OR progress\*). All searches were limited to human studies.

Eligible studies met the following criteria: (i) They were observational studies (retrospective or prospective) or clinical trials, (ii) the studies were limited to lymphoma, (iii) ^18^F-FDG PET was used as an initial imaging tool, (iv) patients had not undergone chemotherapy, immune-chemotherapy or radiotherapy before the ^18^F-FDG PET scan, (v) the volume of the lymphoma was measured, (vi) the survival data was reported. Studies were excluded if: (i) they were case reports, case series, review articles, editorials, letters or comments; (ii) the patient survival data was unavailable or insufficient to perform the meta-analysis, (iii) the data included was specifically for HIV-associated lymphoma, pediatric lymphoma, primary central nervous system lymphoma, primary testicular lymphoma, or primary mediastinal large B-cell lymphoma, or (iv) they included overlapping patients and data. Two reviewers (B.P. Guo and Q. Ke) independently selected the literature using a standardized protocol. Disagreements were resolved by discussion.

Quality assessment {#sec004}
------------------

The methodological quality of the primary manuscripts was independently evaluated by two reviewers (B.P. Guo and X.H. Tan) by means of the Newcastle-Ottawa-Scale (NOS) \[[@pone.0210224.ref024]\], which is used for the quality assessment of cohort and case-control studies. The NOS comprises three quality parameters: selection (0--4 points), comparability (0--2 points), and outcome assessment (0--3 points). Studies with scores of six or more were considered to be of high quality. Any disparities between investigators were resolved by discussion. Study quality was not an exclusion criterion.

Data extraction {#sec005}
---------------

Data extraction was carried out by B.P Guo and independently confirmed by the other authors (X.H. Tan and H. Cen). The collected data included the following: Study characteristics: first author, year of publication, country, study design, imaging modalities, type of lymphoma, number of patients, treatment, tumor volume parameters (maximum threshold for PET volume auto-segmentation, and median MTV/TLG), MTV/TLG cut-off values, determination of MTV cut-off, median follow-up, and endpoints. Extracted data were entered onto a standardized Excel file (Microsoft Corporation). Discrepancies were resolved by discussion with coauthors.

We chose OS and PFS as endpoints for our meta-analysis. Overall survival is defined as the length of time from either the date of diagnosis or the date of recruitment in a study to the moment of death as a result of any cause. PFS is defined as the length of time from either the date of diagnosis or the date of recruitment in a study until lymphoma progression or death as a result of any cause.

Statistical analysis {#sec006}
--------------------

The impact of MTV or TLG on survival was measured by estimating the effect size of the hazard ratios (HR). Pooled HRs of more than 1.00 indicated poor survival in the group with high MTV or TLG values when compared with the group with low values. For studies in which the HRs and CIs were not available, we used the method proposed by Parmar et al. \[[@pone.0210224.ref025]\] to derive estimates from survival curves. The point estimate of the HR was considered statistically significant at the *p*\< 0.05 level if the 95% CI did not include the value 1.

Heterogeneity was assessed by means of Cochran *Q* and *I*^*2*^ statistics. I-square (*I*^*2*^) values of \<30%, 30%-50%, 50%-75% and \>75% were defined as low, moderate, substantial and considerable heterogeneity, respectively \[[@pone.0210224.ref026]\]. If heterogeneity existed between primary studies, a random effects model was used. Otherwise, a fixed effects model was used for the meta-analysis. Publication bias was assessed by visual inspection of the funnel plot and also by means of the Begg and Egger tests \[[@pone.0210224.ref027],[@pone.0210224.ref028]\]. A p-value less than 0.05 indicates the existence of publication bias. All statistical analyses were performed by using RevMan 5.3 (Nordic Cochrane Centre).

Results {#sec007}
=======

Literature search procedure {#sec008}
---------------------------

The PRISMA statement flowchart shows the process of literature screening and selection, as well as the reasons for exclusion ([Fig 1](#pone.0210224.g001){ref-type="fig"}). Our initial search yielded 5045 articles. After removing duplicates and screening the titles and abstracts, 45 articles were reviewed in more detail. Of the 45 full-text studies, 18 were excluded for the following reasons: 7 studies had incomplete or unavailable data and other topics; 5 reports were reviews and editorials; 1 study involved pediatric lymphoma; 3 studies included primary extranodal lymphoma and relapsed or refractory lymphoma; 2 studies were multiple publications. After reviewing the full texts, 27 studies were finally selected as potentially appropriate for inclusion in the meta-analysis \[[@pone.0210224.ref015]--[@pone.0210224.ref022],[@pone.0210224.ref029]--[@pone.0210224.ref047]\].

![Flow diagram of the systematic review and meta-analysis process.](pone.0210224.g001){#pone.0210224.g001}

Study characteristics {#sec009}
---------------------

The 27 observational studies fulfilled the inclusion criteria, were published between 2012 and 2018 and are summarized in [Table 1](#pone.0210224.t001){ref-type="table"}. Twenty-five studies were retrospective observational studies, and three studies were prospective multicenter trials. Seventeen studies included patients with diffuse large B cell lymphoma, three included patients with follicular lymphoma, one included patients with peripheral T-cell lymphoma, four studies included patients with extranodal natural killer/T cell lymphoma, and three studies included patients with Hodgkin lymphoma. The total sample size was 2729. Either TMTV or TLG was measured in 12 studies, and both were measured in 15 studies.

10.1371/journal.pone.0210224.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0210224.t001){#pone.0210224.t001g}

  Study                                               Year   Country      Study Design   NOS   Type of Lymphoma                            Patients (No.)   Treatment regimen                Tumor Volume Parameters(MTV/TLG)                           Cut-off values                               Determination of MTV Cut off                  Endpoints        Median follow-up                                       
  --------------------------------------------------- ------ ------------ -------------- ----- ------------------------------------------- ---------------- -------------------------------- ---------------------------------------------------------- -------------------------------------------- --------------------------------------------- ---------------- ------------------ ------------------------- --------- -------------------
  Song et al.[^a^](#t001fn005){ref-type="table-fn"}   2012   Korea        R              8     DLBCL                                       169              R-CHOP                           ≥2.5                                                       198.1                                        NR                                            220              NR                 ROC analysis              PFS/OS    36 months
  Manohar et al.                                      2012   India        R              6     NHL[^§^](#t001fn004){ref-type="table-fn"}   51               R-CHOP-like                      Background- level [^†^](#t001fn003){ref-type="table-fn"}   957                                          5356                                          416              3340               ROC analysis              PFS/OS    12 months
  Kim et al.                                          2013   Korea        R              8     DLBCL                                       140              R-CHOP                           Various[^‡^](#t001fn002){ref-type="table-fn"}              NR                                           415.5                                         NR               415.5              N/A                       PFS/OS    28.5 months
  Oh et al.                                           2013   Korea        R              6     DLBCL                                       181              R-CHOP                           ≥2.5                                                       156.89                                       NR                                            65.975           NR                 ROC analysis              PFS/OS    NR
  Song et al.                                         2013   Korea        R              7     HL                                          127              ABVD                             ≥2.5                                                       142.6                                        NR                                            198              NR                 ROC analysis              PFS/OS    45.8 months
  Kim et al.                                          2013   Korea        R              5     ENKTL                                       20               CTx follow RT/ Only CTx          NR                                                         10.7                                         46.9                                          14.4             52.7               ROC analysis              PFS/OS    26.3 months
  Esfahani et al.                                     2013   USA          R              7     DLBCL                                       20               R-CHOP                           50                                                         379.16                                       704.77                                        379.16           704.77             ROC analysis              PFS       mean 51.35 months
  Sasanelli et al.                                    2014   France       R              9     DLBCL                                       114              R-CHOP/ R-ACVBP                  41                                                         315                                          2974                                          550              4,576              ROC analysis              PFS/OS    39 months
  Gallicchio et al.                                   2014   Italy        R              5     DLBCL                                       52               R-CHOP-like                      42                                                         43                                           596.9                                         16.1             589.5              ROC analysis              EFS/OS    18 months
  Kim et al.                                          2014   Korea        R              5     DLBCL                                       96               R-CHOP                           ≥2.5                                                       130.7                                        NR                                            130.7            NR                 ROC analysis              EFS/OS    27.8 months
  Adams et al.                                        2015   Netherland   R              9     DLBCL                                       73               R-CHOP                           40                                                         272                                          2955.4                                        272              2955.4             ROC analysis              PFS/OS    2.7years
  Schoder et al.                                      2015   USA          P              6     DLBCL                                       65               R-CHOP                           Various[^‡^](#t001fn002){ref-type="table-fn"}              226                                          NR                                            NR               NR                 N/A                       PFS/OS    51 months
  Kanoun et al.                                       2015   France       R              8     HL                                          59               CTx ± RT                         Various[^‡^](#t001fn002){ref-type="table-fn"}              160                                          NR                                            313              NR                 ROC analysis              PFS/OS    39 months
  Mikhaeel et al.                                     2016   UK           R              8     DLBCL                                       147              R-CHOP                           41                                                         595                                          4669.5                                        396              4541               ROC analysis              PFS       3.8 years
  Zhou et al.                                         2016   China        R              8     DLBCL                                       91               R-CHOP                           Background-level [^†^](#t001fn003){ref-type="table-fn"}    50.7                                         497.3                                         PFS: 70 OS: 78   PFS: 827 OS: 726   ROC analysis              PFS/OS    30 months
  Song et al.^b^                                      2016   Korea        R              6     DLBCL                                       107              R-CHOP                           ≥2.5                                                       526.8                                        NR                                            601.2            NR                 ROC analysis              PFS/OS    40.8 months
  Cottereau et al.                                    2016   France       R              8     PTCL                                        108              CHOP-like/ ACVBP                 41                                                         224                                          1155                                          230              1068               ROC analysis              PFS/OS    23 months
  Meignan et al.                                      2016   France       R              9     FL 1-3a                                     185              R-CHOP/ R-CVP/R-FM               41                                                         297                                          NR                                            510              NR                 X-tile analysis           PFS/OS    64 months
  Chang et al.                                        2017   China        R              6     ENKTL                                       52               DDGP/SMILE                       40                                                         11.2                                         46.4                                          16.1             44.7               ROC analysis              PFS/OS    19 months
  Chang et al.                                        2017   Taiwan       R              7     DLBCL                                       118              R-CHOP                           ≥2.5                                                       550.4[\*](#t001fn006){ref-type="table-fn"}   3533.2[\*](#t001fn006){ref-type="table-fn"}   165.4            1204.9             ROC analysis              PFS/OS    28.7 months
  Kesavan et al.                                      2017   Australia    P              7     FL                                          68               Iodine-131-rituximab             41                                                         510                                          NR                                            510              NR                 NR                        TTNT/OS   59 months
  Song et al.                                         2017   Korea        R              5     ENKTL                                       100              CTx follow RT/CTx                ≥2.5                                                       36.2                                         NR                                            94.2             NR                 ROC analysis              PFS/OS    NR
  Cottereau et al.                                    2018   France       P              9     HL                                          258              ABVD                             41                                                         67                                           332                                           147              495                X-tile and ROC analysis   PFS/OS    55 months
  Ding et al.                                         2018   China        R              7     DLBCL                                       72               R-CHOP                           40                                                         139.48                                       1413.77                                       67.71            1413.77            ROC analysis              PFS/OS    45 months
  Toledano et al.                                     2018   France       R              8     DLBCL                                       114              R-CHOP/ R-CHOP-like              41                                                         275.8                                        NR                                            261.4            1325.80            ROC analysis              PFS/OS    40 months
  Delfau-Larue et al.                                 2018   France       R              8     FL                                          133              R-CHOP/ R-CHOP-like/Chemo-free   41                                                         354                                          NR                                            510              NR                 X-tile and ROC analysis   PFS/OS    48 months
  Pak et al.                                          2018   Korea        R              7     ENKTL                                       36               NR                               40                                                         NR                                           NR                                            7                45.8               NR                        RFS/OS    20.6 months

PET/CT, positron emission tomography/computed tomography; MTV, metabolic tumor volume; TLG, total lesion glycolysis; NOS, the Newcastle-Ottawa-Scale; DLBCL, diffuse large B cell lymphoma; HL, hodgkin lymphoma; NHL, non-hodgkin's lymphoma; ENKTL, extranodal natural killer/T cell lymphoma; PTCL, peripheral T-cell lymphoma; FL, follicular Lymphoma; R, retrospective; P, prospective; NR, not reported; PFS, progression-free surviva; TTNT:time-to-next-treatment; IQR, interquartile range; ROC, receiver operator curve; N/A, not applicable; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; ABVD, doxorubicin,bleomycin, vinblastine, dacarbazine; CTx, chemotherapy; RT, radiotherapy; R-ACVBP: rituximab, doxorubicine, vindesine, cyclophosphamide, bleomycin, prednisolone; R-ICE, rituximab, etoposide, ifosfamide, carboplatin; R-CVP, rituximab, cyclophosphamide, vincristine and prednisolone; R-FM, rituximab, fludarabine and mitoxantrone; DDGP, dexamethasone, cisplatin, gemcitabline and pegaspargase; SMILE, dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide;

^‡^ tested various proposed thresholds, including 41%;

^†^ MTV was measured by setting the tumor marginal threshold of liver SUVmean plus 3SDs. SUVmean in liver was calculated in a standard-sized ROI of 3cm in diameter;

^§^ Of the 51 patients, 39 (77%) had DLBCL, 8 had anaplastic large T-cell lymphoma and 4 had high-grade peripheral T-cell lymphoma.

^a^, In staged II and III patients without extranodal site involvement; b, In patients with bone marrow involvement of lymphoma.

\*The mean values of total MTV and TLG were 550.4 ± 678.3 cm3 and 3533.2 ± 4394.1 cm3 respectively.

Three thresholding methods for the auto segmentation of PET volumes exist. A fixed SUV of 2.5 was used in 7 studies, the percentage of SUVmax (40%, 41%, 42% or 50%) was used in 18 studies, and in 2 studies the MTV was measured by setting the tumor margin threshold as the liver SUVmean plus 3SDs. In each study, patients were divided into 2 groups (high and low volume) based on the cut-off values. The MTV and TLG cut-off values were determined by means of receiver operating curve (ROC) and X-tile analyses. Receiver operating characteristics (ROCs) was used in 19 studies, receiver-operating characteristics and X-tile analysis in 3 studies, X-tile analysis in 1 study, and 4 studies did not provide cut-off information. The MTV cut-off values ranged between 10.7 and 595 cm^3^ and the TLG values ranged from 46.4 to 5356. The study quality assessed by means of the NOS was fair, with a median quality score of 8 (range 5--9).

Prognostic value of baseline metabolic tumor volume {#sec010}
---------------------------------------------------

Twenty-one studies \[[@pone.0210224.ref015]--[@pone.0210224.ref019],[@pone.0210224.ref021],[@pone.0210224.ref022],[@pone.0210224.ref029],[@pone.0210224.ref030]--[@pone.0210224.ref035],[@pone.0210224.ref037],[@pone.0210224.ref039],[@pone.0210224.ref043]--[@pone.0210224.ref047]\] on adult lymphoma were included for the analysis of the relationship between TMTV and PFS. The results of our meta-analysis showed that a high TMTV was associated with a shorter PFS than a low TMTV, with a pooled HR of 3.05 (95% CI, 2.55--3.64, *p*\<0.00001). No significant heterogeneity was found across studies (*I*^*2*^ = 0.0%, *P* = 0.78). Twenty-one studies \[[@pone.0210224.ref015],[@pone.0210224.ref017]--[@pone.0210224.ref020],[@pone.0210224.ref022],[@pone.0210224.ref029]--[@pone.0210224.ref035],[@pone.0210224.ref038]--[@pone.0210224.ref040],[@pone.0210224.ref043]--[@pone.0210224.ref047]\] reported data on TMTV and OS in adult lymphoma. The meta-analysis results demonstrated that a high TMTV was associated with shorter OS than a low TMTV, with a pooled HR of 3.07 (95%CI, 2.47--3.82, *p*\<0.00001). No significant heterogeneity was found across studies (*I*^*2*^ = 0.0%, *p* = 0.60; [Fig 2](#pone.0210224.g002){ref-type="fig"}).

![Meta-analysis of the hazard ratios for PFS, and OS for high TMTV vs low TMTV.\
Hazard ratios and 95% confidence intervals from individual studies are depicted as squares and horizontal lines, respectively. The pooled estimate is shown as a diamond shape, where the center represents the pooled HR and the horizontal borders represent the 95% CI. Hazard ratios are defined as high TMTV vs low TMTV, therefore a hazard ratio \>1 represents a higher risk of death or progression associated with high TMTV. TMTV = total metabolic tumor volume, OS = overall survival, PFS = progression-free survival, CI = confidence interval.](pone.0210224.g002){#pone.0210224.g002}

Next, we examined the relationship between TMTV and the clinical outcome of different types of lymphomas. A meta-analysis of thirteen studies of DLBCL patients showed poorer PFS and OS in patients with high TMTV than in those with low TMTV, with pooled HRs for PFS and OS of 2.93 (95%CI, 2.29--3.73, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.481) and 3.52 (95%CI, 2.67--4.64, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.806), respectively. Three studies examined the prognostic significance of high TMTV in FL patients, and the pooled HRs for PFS and OS were 2.55 (95%CI, 1.65--3.92, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.622) and 2.89 (95%CI, 1.04--7.99, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.419), respectively. Four studies assessed the prognostic significance of high TMTV in ENKL patients, and the pooled HRs for PFS and OS were 3.25 (95%CI, 1.75--6.07, *p*\<0.001; heterogeneity: *I*^*2*^ = 10.7%, *p* = 0.340) and 2.24 (95%CI, 1.23--4.08, *p* = 0.008; heterogeneity: *I*^*2*^ = 24%, *p* = 0.267), respectively. Two studies investigated the prognostic significance of high TMTV in HL patients, and the pooled HR for PFS was 3.89 (95%CI, 2.19--6.90, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.646) ([Table 2](#pone.0210224.t002){ref-type="table"}). Notably, only one study provided relevant data on the correlation between TMTV and PTCL outcome and only one study provided data on the correlation between TMTV and OS in HL patients; therefore, the pooled analysis could not be performed.

10.1371/journal.pone.0210224.t002

###### Pooled hazard ratios for PFS and OS according to TMTV.

![](pone.0210224.t002){#pone.0210224.t002g}

  Study selection        N    PFS                N of cohorts   OS                                                      
  ---------------------- ---- ------------------ -------------- ------ ------- ---- ------------------ --------- ------ -------
  **Type of Lymphoma**                                                                                                  
  DLBCL                  12   2.93(2.29--3.73)   \<0.001        0      0.481   13   3.52(2.67--4.64)   \<0.001   0      0.806
  FL                     3    2.55(1.65--3.92)   \<0.001        0      0.622   2    2.89(1.04--7.99)   \<0.001   0      0.419
  PTCL                   1    4.16(2.25--7.68)   \<0.0001       \-     \-      1    2.35(1.10--5.04)   0.028     \-     \-
  ENKTL                  4    3.25(1.75--6.07)   \<0.001        10.7   0.34    4    2.24(1.23--4.08)   0.008     24     0.267
  HL                     2    3.89(2.19--6.90)   \<0.001        0      0.646   1    3.90(1.60--9.50)   0.0032    \-     \-
  **Study Design**                                                                                                      
  Retrospective          19   3.20(2.64--4.01)   \<0.001        0      0.774   17   3.21(2.54--4.07)   \<0.001   0      0.743
  Prospective            3    2.81(1.72--4.59)   \<0.001        11.2   0.342   3    1.91(0.51--7.15)   0.337     23.1   0.273
  **Sample size**                                                                                                       
  ≥100                   11   3.51(2.78--4.42)   \<0.001        0      0.667   10   3.59(2.70--4.76)   \<0.001   0      0.531
  \<100                  7    2.82(1.99--3.99)   \<0.001        0      0.55    9    2.45(1.65--3.65)   \<0.001   0      0.809
  **Threshold**                                                                                                         
  ≥2.5                   5    3.93(2.76--5.60)   \<0.001        0      0.553   5    3.65(2.38--5.61)   \<0.001   28.9   0.229
  41                     6    2.56(1.83--3.58)   \<0.001        0      0.554   5    3.56(2.22--5.70)   \<0.001   0      0.772
  40                     3    2.19(1.21--3.98)   0.01           0      0.98    3    1.80(0.84--3.83)   0.129     5      0.349
  other                  4    3.20(2.02--5.05)   \<0.001        0      0.753   4    3.69(1.89--7.22)   \<0.001   0      0.817

N: number of studies; HR: hazard ratio; 95% CI: 95% confidence interval; P~*H*~: p values of Q test for heterogeneity test; OS: Overall survival; PFS: Progression free survival.

We also conducted subgroup analyses stratified by data collection method, sample size, and different threshold values. The subgroup analysis of retrospectively collected data showed pooled HRs for PFS and OS of 3.20 (95%CI, 2.64--4.01, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.774) and 3.21 (95%CI, 2.54--4.07, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.743), respectively. The prospectively collected data showed pooled HRs for OS and PFS of 2.81 (95%CI, 1.72--4.59, *p*\<0.001; heterogeneity: *I*^*2*^ = 11.2%, *p* = 0.342) and 1.91 (95%CI, 0.51--7.15, *p* = 0.337; heterogeneity: *I*^*2*^ = 23.1%, *p* = 0.273), respectively. The subgroup analysis performed on the basis of sample size showed that the negative predictive value of high TMTV on PFS and OS was present both in samples with sizes ≥100 (PFS, HR: 3.51, 95%CI: 2.78--4.42, *p*\<0.001; OS, HR: 3.59, 95%CI: 2.70--4.76, *p*\<0.001) and \<100 (PFS, HR: 2.82, 95%CI: 1.99--3.99, *p*\< 0.001; OS, HR: 2.45, 95%CI:1.65--3.65, *p*\<0.001). Lastly, the subgroup analyses by thresholds (≥ 2.5, 40%, 41%, and others) demonstrated that a high TMTV was associated with shorter PFS and OS than a low TMTV ([Table 2](#pone.0210224.t002){ref-type="table"}).

Prognostic value of baseline total lesion glycolysis {#sec011}
----------------------------------------------------

Ten studies \[[@pone.0210224.ref015]--[@pone.0210224.ref017],[@pone.0210224.ref020],[@pone.0210224.ref022],[@pone.0210224.ref029],[@pone.0210224.ref032],[@pone.0210224.ref037],[@pone.0210224.ref043],[@pone.0210224.ref046]\] were included for the analysis of the relationship between TLG and PFS in adult lymphoma. The results of our meta-analysis showed that high TLG values were associated with shorter PFS than low TLG values, with a pooled HR of 3.44 (95%CI, 2.37--5.01, *p*\<0.00001). There was moderate heterogeneity across the studies, but it did not reach statistical significance (*I*^*2*^ = 41.0%, *p* = 0.08). Twelve studies \[[@pone.0210224.ref015],[@pone.0210224.ref017],[@pone.0210224.ref020],[@pone.0210224.ref022],[@pone.0210224.ref029],[@pone.0210224.ref032],[@pone.0210224.ref034],[@pone.0210224.ref037],[@pone.0210224.ref038],[@pone.0210224.ref040],[@pone.0210224.ref043],[@pone.0210224.ref046]\] reported data on TLG and OS in adult lymphoma. Because significant heterogeneity was found across the studies (*I*^*2*^ = 62.0%, *P* = 0.002), a pooled HR of 3.08 (95%CI, 1.84--5.16, *p =* 0.0001) was calculated on the basis of a random-effects model ([Fig 3](#pone.0210224.g003){ref-type="fig"}).

![Meta-analysis of the hazard ratios for PFS and OS for high TLG vs low TLG.\
Hazard ratios and 95% confidence intervals for death or progression associated with high vs low TLG. TLG = total lesion glycolysis, OS = overall survival, PFS = progression-free survival, CI = confidence interval.](pone.0210224.g003){#pone.0210224.g003}

Next, we examined the prognostic significance of TLG on different types of lymphomas. A meta-analysis of seven and eight studies involving DLBCL patients showed poorer PFS and OS in those with high TMTV values than in those with low TMTV values, with pooled HRs for OS and PFS of 3.06 (95%CI, 1.52--6.18, *p* = 0.002; heterogeneity: *I*^*2*^ = 67.3%, *p* = 0.003) and 2.93 (95%CI, 1.89--4.53, *p*\<0.001; heterogeneity: *I*^*2*^ = 49.5%, *p* = 0.065), respectively. Three studies examined the prognostic significance of high TLG values in ENKL patients, and the pooled HRs for PFS and OS were 2.99 (95%CI, 1.83--4.89, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.503) and 2.58 (95%CI, 1.33--5.01, *p* = 0.005; heterogeneity: *I*^*2*^ = 19.0%, *p* = 0.291), respectively ([Table 3](#pone.0210224.t003){ref-type="table"}). Only one study provided relevant data on the correlation between TLG and clinical outcome in PTCL patients and only one study provided data on the correlation between TLG and outcome in HL patients; therefore, the pooled analysis could not be performed.

10.1371/journal.pone.0210224.t003

###### Pooled hazard ratios for PFS and OS according to TLG.

![](pone.0210224.t003){#pone.0210224.t003g}

  Study selection        N    PFS                 N         OS                                                       
  ---------------------- ---- ------------------- --------- ------ ------- ---- ------------------- --------- ------ -------
  **Type of Lymphoma**                                                                                               
  DLBCL                  7    2.93(1.89--4.53)    \<0.001   49.5   0.065   8    3.06(1.52--6.18)    0.002     67.3   0.003
  PTCL                   \-   \-                  \-        \-     \-      \-   \-                  \-        \-     \-
  ENKTL                  3    2.99(1.83--4.89)    \<0.001   0      0.503   3    2.58(1.33--5.01)    0.005     19     0.291
  HL                     1    6.90(2.59--18.36)   0.0001    \-     \-      1    10.9(3.29--36.23)   0.0001    \-     \-
  **Study Design**                                                                                                   
  Retrospective          10   2.97(2.03--4.35)    \<0.001   35.7   0.122   11   2.28(1.40--3.71)    0.001     50.1   0.029
  Prospective            1    6.90(2.59--18.36)   0.0001    \-     \-      1    10.9(3.29--36.23)   0.0001    \-     \-
  **Sample size**                                                                                                    
  ≥100                   5    4.60(2.83--7.47)    \<0.001   0      0.59    4    3.54(1.56--8.06)    0.003     62.6   0.045
  \<100                  6    2.73(1.53--4.86)    0.001     48.7   0.083   9    2.07(1.21--3.55)    0.008     54.9   0.023
  **Threshold**                                                                                                      
  ≥2.5                   1    6.94(1.41--34.12)   0.017     \-     \-      1    8.63(1.09--68.34)   0.041     \-     \-
  41                     3    4.64(2.44--8.85)    \<0.001   13.9   0.313   1    10.9(3.29--36.23)   0.0001    \-     \-
  40                     3    2.16(0.94--4.96)    0.07      60.6   0.079   3    1.90(0.91--3.98)    0.086     43.7   0.169
  other                  3    4.52(2.48--8.21)    \<0.001   0      0.86    5    3.53(1.98--6.28)    \<0.001   3.1    0.389

N: number of studies; HR: hazard ratio; 95% CI: 95% confidence interval; P~*H*~: p values of Q test for heterogeneity test; OS: Overall survival; PFS: Progression free survival.

We also conducted subgroup analyses stratified by data collection method, sample size, and different threshold values. The subgroup analysis of retrospectively collected data showed pooled HRs for OS and PFS of 2.28 (95%CI, 1.40--3.71, *p* = 0.001; heterogeneity: *I*^*2*^ = 50.1%, *p* = 0.029) and 2.97 (95%CI, 2.03--4.35, *p*\<0.001; heterogeneity: *I*^*2*^ = 35.7%, *p* = 0.122), respectively. Only one study involved prospectively collected data, so the pooled analysis could not be performed. The subgroup analysis conducted by sample size showed that the negative predictive value of high TMTV on PFS and OS was present both in samples with sizes ≥100 (PFS, HR: 4.60, 95%CI: 2.83--7.47, *p*\<0.001; OS, HR: 3.54, 95%CI: 1.56--8.06, *p*\<0.001) and \<100 (PFS, HR: 2.73, 95%CI: 1.53--4.86, *p =* 0.001; OS, HR: 2.07, 95%CI:1.21--3.55, *p =* 0.008). A meta-analysis of three studies with a 40% threshold showed there was a trend for a correlation between high TLG values and lymphoma prognosis, with pooled HRs for OS and PFS of 1.90 (95%CI, 0.91--3.98, *p* = 0.086; heterogeneity: *I*^*2*^ = 43.7%, *p* = 0.169) and 2.16 (95%CI, 0.94--4.96, *p* = 0.07; heterogeneity: *I*^*2*^ = 60.6%, *p* = 0.079), respectively. The meta-analysis of studies using other thresholds (including the liver SUVmean plus 3SDs, 50%) showed a negative correlation between high TLG values and lymphoma prognosis, with pooled HRs for OS and PFS of 3.53 (95%CI, 1.98--6.28, *p*\<0.001; heterogeneity: *I*^*2*^ = 3.1%, *p* = 0.389) and 4.52 (95%CI, 2.48--8.21, *p*\<0.001; heterogeneity: *I*^*2*^ = 0.0%, *p* = 0.860), respectively. The subgroup analysis selecting a 41% threshold showed a negative predictive value of high TLG on PFS, with a pooled HR for PFS of 4.64 (95%CI, 2.44--8.85, *p*\<0.001; heterogeneity: *I*^*2*^ = 13.9%, *p* = 0.313) ([Table 3](#pone.0210224.t003){ref-type="table"}). Only one study used a threshold ≥2.5, so the pooled analysis could not be performed.

Publication bias {#sec012}
----------------

Inspection of the funnel plot and formal statistical tests (**TMTV:** Egger test, ***p*** = **0**.**931**; Begg test, ***p*** = **0.867**; **TLG:** Egger test, ***p*** = **0.200**; Begg test, ***p*** = **0.236**; [Fig 4](#pone.0210224.g004){ref-type="fig"}) showed no evidence of publication bias in the meta-analysis of the prognostic significance of baseline metabolic tumor volume and total lesion glycolysis in adult lymphoma.

![Assessment of publication bias using Funnel plot analysis.\
(a) Funnel plot of hazard ratio for overall survival and progression-free survival for high TMTV (horizontal axis) and the standard error (SE) for the hazard ratio (vertical axis). (b) Funnel plot of hazard ratio for overall survival and progression-free survival for high TLG (horizontal axis) and the standard error (SE) for the hazard ratio (vertical axis). Each study is represented by one circle. The vertical line represents the pooled effect estimate.](pone.0210224.g004){#pone.0210224.g004}

Discussion {#sec013}
==========

Main findings {#sec014}
-------------

This meta-analysis comprehensively and systematically reviewed the current available literature and found that: (1) A high baseline TMTV significantly predicted poor OS and shorter PFS in adult lymphoma patients (p\<0.00001 and p\<0.00001, respectively); (2) A high baseline TMTV was significantly associated with reduced survival in DLBCL patients treated with R-CHOP and predicted poor OS and PFS for different types of lymphomas, such as FL, ENKL and HL. The evidence supporting this association was consistent in most subgroup analyses (retrospective data collection, ethnicity, sample size, and different thresholds). The analysis of prospectively collected data and studies using a 40% threshold suggested a trend towards poor OS; however, these results were not statistically significant; (3) A high baseline TLG significantly predicted poor OS and shorter PFS in adult lymphoma patients (*p*\<0.00001 and *p* = 0.005, respectively); (4) A high baseline TLG was significantly associated with reduced survival in DLBCL patients treated with R-CHOP and predicted poor OS and PFS in different types of lymphomas, such as FL, ENKL and HL. The evidence of this association was consistent in most subgroup analyses (data collection method, ethnicity, sample size, and different thresholds).

Metabolic tumor volumes can be segmented by using various methods, such as a fixed SUV threshold, a percentage (based on the percentage of maximum uptake in the lesion), a threshold adjusted to the tumor-to-background ratio, or a gradient \[[@pone.0210224.ref023]\]. Reproducibility is the key for reliable volumetric tumor segmentation. Different TMTV measurement methods have been used in various types of lymphoma, each with specific advantages and disadvantages. A method based on the 41% SUVmax threshold is recommended by the European Association of Nuclear Medicine (EANM) for TMTV measurement of solid tumors. It has been developed in patients with HL and DLBCL, showing good reproducibility \[[@pone.0210224.ref048]\]. Different thresholding methods were used for PET volume auto-segmentation in the studies included herein; however, a threshold of 41% or 40% of the SUVmax was widely used. In our study, we conducted subgroup analyses stratified by different thresholds (≥2.5, 41%, and others). The results demonstrated that high TMTV or TLG values were associated with shorter PFS and OS. Subgroup stratification based on a threshold of 40% of the SUVmax showed that a high TMTV was a negative predictor of PFS; however, it did not significantly predict poor PFS and OS in the case of TLG.

Baseline MTV by PET/CT, is a promising prognostic indicator in patients with lymphoma, which is better than using size-defined bulk \[[@pone.0210224.ref016], [@pone.0210224.ref033]\]. TLG, which is the MTV multiplied by the mean SUV in the volume, is also prognostic \[[@pone.0210224.ref037]\], but appears no better than MTV in prediction of survival in lymphoma \[[@pone.0210224.ref016]\].

Several retrospective studies have shown that metabolic tumor volume (MTV) is a strong predictor of prognosis irrespective of the method \[[@pone.0210224.ref019],[@pone.0210224.ref021],[@pone.0210224.ref049]\]. However, cut-offs used to divide patients into high and low risk groups by MTV are highly dependent on the patient population and the method used. A fixed 41% SUVmax relative thresholding method has been applied successfully in different subtypes of lymphoma, but probably overestimated the volume of lesions with low SUVmax, particularly for smaller VOIs \[[@pone.0210224.ref019],[@pone.0210224.ref021],[@pone.0210224.ref048]\]. The 2.5 method could include the volume of nontumor regions located between small distant nodes with high uptake \[[@pone.0210224.ref050]\]. The 2.5 method probably overestimated MTV in approximately 12% of patients who had low FDG uptake in the liver or liver involvement by lymphoma \[[@pone.0210224.ref049]\]. Furthermore, the negative and positive predictive values of the 41% method have been shown to be superior to other methods, which results in excellent outcome prediction in other subtypes of lymphoma \[[@pone.0210224.ref021]\]. Generally, current evidence showed that metabolic tumor volume values were significantly influenced by the choice of the method used for determination of volume. However, no significant differences were found in term of prognosis \[[@pone.0210224.ref021]\]. In clinical practice, a consensus on the most accurate method or an optimal cut-off to define the MTV for specific lymphoma subtypes will be required, which will require validation in multicenter prospective trials.

Several methods for autosegmentation of PET volumes exist (e g, threshold-based, gradient-based, statistical, and texture-based methods) \[[@pone.0210224.ref051]\]. All methods have strengths and limitations. Reproducibility is the key for tumor segmentation in routine practice \[[@pone.0210224.ref023]\]. There is no universally accepted reproducible and practical method for tumor segmentation. Recently, Yu et al. reported a new semi-automatic approach that applies first an anatomical multi-atlas segmentation on the CT images to remove the organs having hyper uptake value on PET images. Using a CRFs (Conditional Random Fields) model, the rate of good detection of lymphoma is 100% in 11 patients \[[@pone.0210224.ref052]\]. Meanwhile, this new semi-automatic approach has the best dice index for the real lymphoma regions. However, this new methodology will require prospective validation in sufficiently large patient cohorts.

Among the included studies, there were mainly two different approaches to define the optimal TMTV cut-off value as a predictor of survival: X-tile analysis, receiver operating curve (ROC) analysis, or both. X-tile analysis is the primary approach for reliable cut-point determination. This method creates separate training and validation data sets, improving the robustness of the analysis \[[@pone.0210224.ref053]\]. In the studies included in this meta-analysis, ROC was widely used. This method defines the optimal cut-off point as the value whose sensitivity and specificity are closest to the value of the area under the ROC curve, and for which the absolute value of the difference between the sensitivity and specificity values is minimal. This method is recommended for finding the true cut-off point \[[@pone.0210224.ref054]\]. Meignan et al. \[[@pone.0210224.ref018]\] used another restricted cubic spline to define the optimal TMTV cut-off point. Splines are used to model the relationship between TMTV as a continuous variable and survival time, but their contribution to optimal cut-off point definition is minimal. Subgroup analyses based on different MTV cut-off values demonstrated that patients with a high TMTV had shorter PFS and OS than those with a low TMTV.

A major strength of this meta-analysis is that it complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@pone.0210224.ref055]\]. In addition, we extracted the maximum information from the included studies by a thorough qualitative review and quantitative meta-analysis.

Our study also has some limitations. Firstly, nearly all of the included studies were retrospective, which may result in confounding and detection bias. Secondly, patients with different types of lymphoma were treated with different therapeutic regimes. Thirdly, PET scans were performed using scanners of different generations, which may potentially affect the calculation of the SUV and therefore, of TMTV and TLG as well. Similarly, the FDG uptake times were difficult to standardize. Based on all of the above, the clinical heterogeneity of the included studies could be an issue. Finally, our meta-analysis was based on data from published trials, and we did not obtain individual patient data.

Conclusions {#sec015}
-----------

Our meta-analysis suggests that high baseline metabolic tumor volumes or total lesion glycolysis measured by FDG-PET/CT predict significantly worse overall survival and progression-free survival in patients with lymphoma. Therefore, TMTV and TLG may serve as new prognostic biomarkers. In view of our findings, future clinical trials with patients with different types of lymphoma are warranted to determine whether these novel findings can be integrated into various prognostic models, with the goal of achieving better risk stratification and treatment selection.
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